"Magic Bullets" at the center stage of immune therapy: a special issue on therapeutic antibodies.
作者信息
An Zhiqiang
机构信息
The Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
出版信息
Protein Cell. 2018 Jan;9(1):1-2. doi: 10.1007/s13238-017-0488-1.
Abstract
摘要
相似文献
1
"Magic Bullets" at the center stage of immune therapy: a special issue on therapeutic antibodies.“神奇子弹”处于免疫疗法的核心地位：治疗性抗体特刊
Protein Cell. 2018 Jan;9(1):1-2. doi: 10.1007/s13238-017-0488-1.
2
Immunology. Considering therapeutic antibodies.免疫学。关于治疗性抗体的研究。
Science. 2006 Jul 21;313(5785):308-9. doi: 10.1126/science.1130482.
3
Future prospects of monoclonal antibodies as magic bullets in immunotherapy.单克隆抗体作为免疫疗法中神奇子弹的未来前景。
Hum Antibodies. 2013;22(1-2):9-13. doi: 10.3233/HAB-130266.
4
[Antibodies--the "magic bullets"?].[抗体——“神奇子弹”？]
Pharm Unserer Zeit. 2006;35(1):84-5. doi: 10.1002/pauz.200690017.
5
Therapeutic antibodies: magic bullets hit the target.治疗性抗体：神奇子弹击中目标。
Nature. 2002 Jun 6;417(6889):584-6. doi: 10.1038/417584a.
6
Antitumor Antibodies Can Drive Therapeutic T Cell Responses.抗肿瘤抗体可驱动治疗性T细胞反应。
Trends Cancer. 2017 Sep;3(9):615-620. doi: 10.1016/j.trecan.2017.07.001. Epub 2017 Jul 29.
7
Building better magic bullets--improving unconjugated monoclonal antibody therapy for cancer.打造更优的神奇子弹——改进癌症的非共轭单克隆抗体疗法
Nat Rev Cancer. 2007 Sep;7(9):701-6. doi: 10.1038/nrc2209.
8
Molecular engineering and design of therapeutic antibodies.治疗性抗体的分子工程与设计
Curr Opin Immunol. 2008 Aug;20(4):460-70. doi: 10.1016/j.coi.2008.06.012.
9
From "magic bullets" to specific cancer immunotherapy.从“魔弹”到特异性癌症免疫疗法。
Swiss Med Wkly. 2013 Jan 23;143:w13734. doi: 10.4414/smw.2013.13734. eCollection 2013.
10
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.癌症治疗的未来：免疫调节、嵌合抗原受体（CAR）及联合免疫疗法。
Nat Rev Clin Oncol. 2016 May;13(5):273-90. doi: 10.1038/nrclinonc.2016.25. Epub 2016 Mar 15.
引用本文的文献
1
Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications.mRNA 药物在临床前和临床应用中的进展和前景。
Signal Transduct Target Ther. 2024 Nov 14;9(1):322. doi: 10.1038/s41392-024-02002-z.
2
Constructing immune and prognostic features associated with ADCP in hepatocellular carcinoma and pan-cancer based on scRNA-seq and bulk RNA-seq.基于 scRNA-seq 和 bulk RNA-seq 构建与 HCC 中 ADCP 相关的免疫和预后特征，并进行泛癌分析。
Front Immunol. 2024 May 7;15:1397541. doi: 10.3389/fimmu.2024.1397541. eCollection 2024.
3
Establishing and validating an ADCP-related prognostic signature in pancreatic ductal adenocarcinoma.建立和验证胰腺导管腺癌中与 ADCP 相关的预后标志物。
Aging (Albany NY). 2022 Aug 12;14(15):6299-6315. doi: 10.18632/aging.204221.
4
Current Advancements in Addressing Key Challenges of Therapeutic Antibody Design, Manufacture, and Formulation.治疗性抗体设计、制造和配方关键挑战应对的当前进展
Antibodies (Basel). 2019 Jun 3;8(2):36. doi: 10.3390/antib8020036.
本文引用的文献
1
IgG Fc engineering to modulate antibody effector functions.IgG Fc 工程改造以调节抗体效应功能。
Protein Cell. 2018 Jan;9(1):63-73. doi: 10.1007/s13238-017-0473-8. Epub 2017 Oct 6.
2
Current progress in innovative engineered antibodies.创新工程抗体的最新进展。
Protein Cell. 2018 Jan;9(1):86-120. doi: 10.1007/s13238-017-0457-8. Epub 2017 Aug 18.
3
Molecular and functional analysis of monoclonal antibodies in support of biologics development.支持生物制品开发的单克隆抗体的分子和功能分析。
Protein Cell. 2018 Jan;9(1):74-85. doi: 10.1007/s13238-017-0447-x. Epub 2017 Jul 21.
4
A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys.一种与人类FcRn结合力增强的新型治疗性抗乙肝病毒抗体可改善小鼠和猴子体内的药代动力学。
Protein Cell. 2018 Jan;9(1):130-134. doi: 10.1007/s13238-017-0438-y.
5
Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy.治疗性 IgG 抗体的糖基化工程：安全性、功能性和疗效面临的挑战。
Protein Cell. 2018 Jan;9(1):47-62. doi: 10.1007/s13238-017-0433-3. Epub 2017 Jun 8.
6
Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig.利用 Half DVD-Ig 实现高效且有条件的 redirected T 细胞杀伤肿瘤细胞。
Protein Cell. 2018 Jan;9(1):121-129. doi: 10.1007/s13238-017-0429-z. Epub 2017 Jun 5.
7
Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab.治疗性单克隆抗体度伐利尤单抗独特的程序性死亡受体配体1（PD-L1）结合特性
Protein Cell. 2018 Jan;9(1):135-139. doi: 10.1007/s13238-017-0412-8.
8
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.单克隆抗体和 Fc 融合蛋白的药代动力学。
Protein Cell. 2018 Jan;9(1):15-32. doi: 10.1007/s13238-017-0408-4. Epub 2017 Apr 19.
9
In vitro-engineered non-antibody protein therapeutics.体外工程化的非抗体蛋白治疗药物。
Protein Cell. 2018 Jan;9(1):3-14. doi: 10.1007/s13238-017-0386-6. Epub 2017 Mar 7.
10
Antibody-drug conjugates: recent advances in conjugation and linker chemistries.抗体偶联药物：偶联和连接子化学的最新进展。
Protein Cell. 2018 Jan;9(1):33-46. doi: 10.1007/s13238-016-0323-0. Epub 2016 Oct 14.
Zotero 插件